Transcranial Direct Current Stimulation - what is the evidence for its efficacy and safety?

Abraham P Arul-Anandam1,2, Colleen Loo1,2 and Perminder Sachdev1,3

School of Psychiatry, University of New South Wales, Sydney, Australia
Black Dog Institute, Prince of Wales Hospital, Hospital Road, Randwick, NSW 2031, Australia
Neuropsychiatric Institute, Euroa Centre, Prince of Wales Hospital, Hospital Road, Randwick, NSW 2031, Australia

Corresponding author

F1000 Med Reports2009, 1:58 (doi: 10.3410/M1-58)
Published: 27 Jul 2009

The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/58

Abstract

Transcranial direct current stimulation (tDCS), a non-invasive brain stimulation technique, has emerged in the past decade as a useful investigative and therapeutic technique. A number of recent studies suggest that tDCS is safe and may be efficacious in the treatment of a variety of psychiatric and neurological disorders, including major depressive disorder, chronic neuropathic pain, and stroke. More evidence is necessary, however, before it can be recommended for general clinical application.

Introduction and context

There is increasing interest in the therapeutic and investigative capabilities of non-invasive forms of brain stimulation, such as transcranial direct current stimulation (tDCS). tDCS is a non-invasive brain stimulation technique that applies a mild (1-2 mA) direct electrical current via the scalp to enhance or diminish neuronal excitability. There is strong evidence that neurons underlying the anode are ‘excited’, with resting membrane potential shifting towards depolarisation and an increased rate of spontaneous neuronal firing. By contrast, neurons underlying the cathode are ‘inhibited’, with resting membrane potential shifting towards hyperpolarisation and reduced neuronal firing [1,2]. This phenomenon has been utilised to investigate cortical function by either stimulating cortical regions with anodal stimulation or creating ‘functional lesions’ with cathodal stimulation, and then conducting neuropsychological testing. tDCS has also been investigated as potential treatment for neurological and psychiatric diseases, based on the principle of modulation of the excitability of stimulated cortical regions. Clinical trials using tDCS to treat major depressive disorder (MDD) in the 1960s and 1970s produced inconsistent findings, most likely due to variations in the stimulation techniques used (see [3-5] for reviews). By contrast, two recent randomised controlled trials [6,7] have suggested that tDCS has antidepressant effects and is safe. MDD is a common illness with an approximate lifetime prevalence of 17% and confers a large burden of disease in the community, so the prospect of effective non-invasive physical treatments is of considerable interest.

Recent advances

Transcranial direct current stimulation as treatment

Improved understanding of neuropathology and parameters of stimulation (especially electrode size and placement, stimulation strength and duration) has led to refined tDCS techniques in the past decade. Using these newer techniques, two double-blinded, sham-controlled studies using left prefrontal tDCS (1 and 2 mA, 20 minutes per day for up to 10 days) reported positive results in reducing depressive symptoms [6,7]. One trial reported 69% improvement in mean Hamilton Depression Rating Scale (HDRS) scores after five sessions of active tDCS over 1.5 weeks, compared with 30% improvement in the sham group [6]. Another trial also reported positive findings, with improvement in the active group on HDRS of 40.5%, compared to 10.4% in the sham group, after 10 consecutive weekdays of treatment [7]. Moreover, these differences in outcome between active and sham groups persisted at 1-month follow-up, and an open-label extension of the trial indicated that tDCS had similar efficacy, but more rapid onset, compared to a 6-week course of 20 mg/day fluoxetine, a selective serotonin re-uptake inhibitor antidepressant [8].

A more recent, non-placebo controlled clinical trial involving hospitalised patients with drug-resistant depression at high risk of suicide, referred for electroconvulsive therapy, reported >30% improvement in depression rating scores [HDRS and BDI (Beck Depression Inventory)] after anodal stimulation to the left dorsolateral prefrontal cortex (2 mA, twice-daily, for 5 days) [9]. As this was an uncontrolled study, it is uncertain if administering tDCS twice per day was more efficacious than once-daily treatment.

On the other hand, modern tDCS techniques have failed to replicate the dramatic findings of older clinical trials on mood in healthy subjects. In a double-blind crossover trial, 21 subjects received bilateral frontal tDCS with an extracephalic reference electrode [10]. No significant effects on emotional state, affect, emotional decision-making, arousal and psychomotor function were found.

A recent sham-controlled trial with anodal stimulation to the primary motor cortex (2 mA, 20 minutes, five sessions) has also demonstrated the efficacy of tDCS for the treatment of chronic pain due to spinal cord injury [11]. Interestingly, the analgesic effect appeared to be cumulative, with greatest overall pain reduction after five sessions of treatment. Similar to the depression trial, differences in pain scores between the active and sham group were still present at 2-week follow-up. The same parameters have also been reported to alleviate pain in fibromyalgia [12].

There is also some evidence that tDCS may be effective in improving functional recovery after stroke. A randomised, double-blinded, sham-controlled trial found that cathodal tDCS (2 mA, 10 minutes) to the left frontotemporal region significantly improved performance on a picture-naming task in post-stroke patients with chronic aphasia immediately after stimulation [13].

An animal study in rats demonstrated that cathodal tDCS (100-200 µA, 15-60 minutes) increased the threshold for localised seizure activity, suggesting a potential therapeutic role in epilepsy [14]. The clinical evidence for tDCS treatment of epilepsy in humans, however, remains limited (see [15] for a review).

Transcranial direct current stimulation as an investigatory tool

As a tool for investigating brain function, tDCS can help to clarify the causal links between neuroanatomy and behaviour, adding to evidence from other modalities such as neuroimaging. For example, changes in neuropsychological function during prefrontal tDCS imply that the stimulated areas are involved in the performance of that neuropsychological task. Anodal tDCS to the left prefrontal cortex (1 mA, 10 minutes) was shown to improve performance on a probabilistic classification learning task, which measures the unconscious retrieval of previous experiences [16]. Stimulation using the same parameters also reportedly enhanced working memory in healthy subjects, as measured by a three-back working memory task [17], and in patients with Parkinson's disease [18]. In these ways, tDCS has added to data that implicates the prefrontal cortex in both implicit learning and working memory. There is also some recent evidence that tDCS (1.5 mA, 15 minutes) to the temporoparietal areas in patients with Alzheimer's disease improves recognition memory performance [19].

Mechanisms of action of transcranial direct current stimulation

Recent neuroimaging studies have helped improve our understanding of the mechanisms of tDCS, and may help to further refine tDCS techniques in the future. Imaging modalities, including positron emission tomography [20], functional magnetic resonance imaging [21] and magnetic resonance spectroscopy [22,23] have suggested changes in regional blood flow, glutamatergic neurotransmission and membrane function after tDCS, including in brain regions distal to the site of stimulation.

In particular, it appears that tDCS is able to alter spontaneous neuronal firing rates without producing action potentials during stimulation. This is because the current densities produced by tDCS in the cortex are below the action potential threshold for cortical neurons [24,25]. Animal studies have shown that small voltage gradients from anodal and cathodal currents can respectively increase and decrease spontaneous neuronal firing [1,2]. In humans, tDCS-induced changes in motor-evoked potential are attenuated by drugs that block sodium ion channels, suggesting that stimulation works, in part, by altering resting membrane potential [26,27]. There is also evidence that tDCS produces neuroplastic changes that enhance neurosynaptic transmission by modulating NMDA (N-methyl-D-aspartic acid) receptors (see [3] for a review).

Adverse effects

A structural and diffusion-weighted magnetic resonance imaging study [28] compared the prefrontal cortex before and after anodal and cathodal tDCS, and found no structural alterations or disturbances of the blood-brain barrier, and no reduction in apparent diffusion coefficient values (a marker of cytotoxic oedema). Other studies have reported no significant changes in levels of neuron-specific enolase (a sensitive marker of neuronal damage) immediately or 1 hour after tDCS [29]. Common side effects include mild headache, itching and erythema at the electrode site. There are no published reports of tDCS inducing seizure. For a comprehensive review of safety considerations, see [30].

Implications for clinical practice

The experimental findings described suggest that tDCS may emerge as a non-invasive therapeutic modality in the future, particularly for MDD, though there is a need for further replication in clinical trials, and clarification of the subgroup of patients most likely to benefit, before it can be recommended for clinical use. With a stronger evidence base, tDCS may present an attractive addition or alternative to available treatments for depression, particularly given its comparatively mild side-effect profile. For example, it may have a role in the treatment of patients unable to tolerate the side effects of antidepressant medications, and possibly in medication-refractory depression, if subsequent trials show efficacy in this subgroup. Moreover, tDCS has several advantages over other non-invasive forms of brain stimulation, such as transcranial magnetic stimulation: it is less expensive, less cumbersome and, therefore, more mobile, and may have longer lasting effects [31]. tDCS could thus be relatively easily implemented in a clinical setting. The evidence base is currently small, however, and more studies are needed before it can be recommended for general clinical application. In particular, a large multi-centric clinical trial is warranted to establish its efficacy and clinical utility. It is also too early to say whether optimal stimulation parameters have been discovered, and further work is necessary to establish this.

Abbreviations

BDI, Beck Depression Inventory; HDRS, Hamilton Depression Rating Scale; NMDA, N-methyl-D-aspartic acid; MDD, major depressive disorder; tDCS, transcranial direct current stimulation.


Mind controls: Running electricity through the skull

April 2011 by David Robson
Magazine issue 2807.

It sounds too good to be true: changing the brain's activity simply by placing electrodes on the surface of the scalp. But that's the idea behind transcranial direct current stimulation (tDCS). No scalpel required.

With this technique, the electrodes are simply damp sponges about 4 square centimetres in area, and they are used to deliver a current of just a couple of milliamps. "There may be some mild tinglings under the electrodes, but that's about it," says Leonardo Cohen at the National Institutes of Health in Bethesda, Maryland.

tDCS should not be confused with electroconvulsive therapy, where a much larger shock of 600 milliamps is applied to the whole brain. ECT is designed to trigger seizures and must be done under a general anaesthetic. It has side effects such as memory loss and confusion and so is only given to people with very serious depression.

So how does tDCS work? Neurons underneath the positively charged electrode are stimulated to fire more frequently in response to normal incoming signals. The negative electrode has the opposite effect, quietening the underlying cells. If one region needs to be boosted without muting another, the negative electrode can be placed over a thicker part of the skull, such as the area above the eye, to minimise impact.

As tDCS has only been used for about a decade its full potential is still unknown. Perhaps the most widely tested medical use has been to treat brain damage arising from a stroke. In a study on 10 people, five consecutive days of treatment led to improvements in language a week later (Stroke, vol 41, p 1229). The technique is also being investigated as a treatment for depression, chronic pain and migraine.

Because tDCS seems so safe it is being studied as a potential cognitive enhancer. For example, Cohen has shown it can help people learn a task involving precise hand movements: people who had tDCS during the training period performed better than their peers three months down the line (Proceedings of the National Academy of Sciences, vol 106, p 1590). Another group has shown it can boost mathematical skills (Current Biology, vol 20, p 2016).

VERDICT: The equipment is simple and cheap, and the technique looks safe. Perhaps it has the most potential for cognitive enhancement.

Mind controls: Electrodes sitting on the brain's surface

April 2011 by Clare Wilson
Magazine issue 2807.

Pushing electrodes deep into the brain allows precision targeting but requires risky surgery. Placing electrodes on the surface of the scalp carries little-to-no health risk, but it cannot be focused on an area of less than 4 square centimetres. Could we get the best of both worlds through epidural cortical stimulation?

With this technique, rather than placing the electrodes inside the brain, they are put on its surface. So while surgery is needed, it is a safer procedure: a hole is drilled in the skull and a tape with several electrodes on it is slid over the brain's surface membrane, the dura mater. "Dura is Latin for 'tough'," says Mark George, a neuropsychiatrist at the Medical University of South Carolina. "It's pretty safe."

Epidural cortical stimulation is being investigated as a treatment for several conditions, including intractable pain and epilepsy. George's team has recently tested it in five people with severe depression who hadn't responded to drugs or other forms of brain stimulation. Three improved significantly and remained better a year later (Biological Psychiatry, vol 67, p 101).

VERDICT: It could become a safer alternative to deep brain stimulation for conditions where the brain region involved is near the surface.